Overview
Deep Genomics is a pioneer in the AI-driven drug discovery space, specifically focusing on the intersection of deep learning and genomic biology. Their proprietary 'BigBear' platform represents one of the most advanced biological foundation models in existence, capable of predicting how genetic variations influence cellular processes such as RNA splicing, protein binding, and translation. Unlike traditional drug discovery which relies on high-throughput screening of existing libraries, Deep Genomics utilizes a 'predictive' approach to design antisense oligonucleotides (ASOs) that can correct the root causes of genetic diseases. By 2026, the company has solidified its position as a primary partner for global pharmaceutical firms, moving beyond rare monogenic diseases into more complex polygenic conditions. Their technical architecture leverages massive datasets of genomic sequences and cellular phenotypes to simulate millions of genetic mutations, identifying therapeutic targets that would be invisible to human researchers. The platform's ability to model the 'non-coding' genome—once considered junk DNA—has unlocked entirely new classes of druggable targets, making them a cornerstone of the programmable medicine era.